HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) Jun 05, 2024 09:00 HKT/SGT Read More
BIO24에서 발표된 새로운 연구에서 내부 규제 사항을 갖춘 CRO는 생명공학 기업에게 30%의 절감을 제공하고, 시간을 절반으로 줄이며, 위험을 줄입니다 Jun 04, 2024 22:56 HKT/SGT Read More
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs Jun 04, 2024 22:00 HKT/SGT Read More
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform Jun 03, 2024 14:22 HKT/SGT Read More
エーザイ、TIME 誌による「最も影響力のある 100 社(TIME100 MOST INFLUENTIAL COMPANIES)」に選定 Jun 03, 2024 14:00 JST Read More
Avance Clinical, Julius Clinical과 함께 유럽에서 중추신경계(CNS), 심장대사 및 희귀 질환 전문 CRO 서비스를 확장하다 Jun 01, 2024 06:00 HKT/SGT Read More
Avance Clinical透過與Julius Clinical合作,在歐洲擴展專門的中樞神經系統、心血管代謝和罕見疾病的CRO服務 Jun 01, 2024 06:00 HKT/SGT Read More
Avance Clinical通过与Julius Clinical合作,在欧洲扩展专门的中枢神经系统、心血管代谢和罕见疾病的CRO服务 Jun 01, 2024 06:00 HKT/SGT Read More
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical May 31, 2024 16:00 HKT/SGT Read More
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project May 28, 2024 18:00 HKT/SGT Read More
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea May 28, 2024 14:19 HKT/SGT Read More
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim May 16, 2024 22:00 HKT/SGT Read More
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status May 15, 2024 10:19 HKT/SGT Read More
AsiaMedic partners with Sunway to establish new diagnostic imaging centre May 14, 2024 18:00 HKT/SGT Read More
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures May 13, 2024 16:06 HKT/SGT Read More